研究单位：[1]LianBio LLC[2]Anhui Provincial Cancer Hospital,Hefei,Anhui,China,230031[3]The Second Hospital of Anhui Medical University,Hefei,Anhui,China,230601[4]Beijing Cancer Center,Beijing,Beijing,China,100142[5]The First Affiliated Hospital of Xiamen University,Xiamen,Fujian,China[6]The Second Hospital Lanzhou University,Lanzhou,Gansu,China,730030[7]Dongguan City People's Hospital,Dongguan,Guangdong,China,523059[8]Guangzhou First People's Hospital,Guangzhou,Guangdong,China,510180[9]The Sixth Affiliated Hospital, Sun Yat-sen University,Guangzhou,Guangdong,China,510655[10]The Second Affiliated Hospital of Guilin Medical University,Guilin,Guangxi,China,541199[11]Liuzhou People's Hospital,Liuzhou,Guangxi,China,545006[12]Affiliated Hospital of Hebei University,Baoding,Hebei,China,071030[13]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150081[14]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450052[15]Tongji Hospital, Tongji Medical College of HUST,Wuhan,Hubei,China,430030[16]Hubei Cancer Hospital,Wuhan,Hubei,China,430079[17]Hunan Provincial People's Hospital,Changsha,Hunan,China,410002[18]Nanjing Drum Tower Hospital,Nanjing,Jiangsu,China,210008[19]Jilin Cancer Hospital,Changchun,Jilin,China,130012[20]The First Hospital of China Medical University,Shenyang,Liaoning,China,110002[21]The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an,Shaanxi,China[22]Central Hospital Affiliated to Shandong First Medical University,Jinan,Shandong,China,250013[23]Shandong Provincial Cancer Hosptial,Jinan,Shandong,China,250117[24]The Affiliated Hospital of Qingdao University,Qingdao,Shandong,China,266000[25]Zhongshan Hospital Fudan University,Shanghai,Shanghai,China,200032[26]Shanxi Provincial Cancer Hospital,Taiyuan,Shanxi,China,030013[27]West China Hospital of Sichuan University,Chengdu,Sichuan,China,610041[28]Sichuan Cancer Hospital,Chengdu,Sichuan,China,610042[29]Tianjin Medical University Cancer Institute&Hospital,Tianjin,Tianjin,China,300060[30]Yunnan Cancer Hospital,Kunming,Yunnan,China,650118[31]The First Affiliated Hospital Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310013
This is a multicenter, open-label, single arm phase II study to evaluate the efficacy and safety of Infigratinib in patients with locally advanced or metastatic GC or GEJ patient with FGFR2 gene amplification, who have failed at least 2 lines of previous standard systemic treatment .
